Mostrar o rexistro simple do ítem
Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort
dc.contributor.author | Rotea-Salvo, Sandra | |
dc.contributor.author | Martínez-Pradeda, Alejandro | |
dc.contributor.author | Fernández-Oliveira, Carla | |
dc.contributor.author | Giménez-Arufe, Víctor | |
dc.contributor.author | Balboa-Barreiro, Vanesa | |
dc.contributor.author | Margusino-Framiñán, Luis | |
dc.contributor.author | Mena-De-Cea, Álvaro | |
dc.contributor.author | Vázquez-Rodríguez, Pilar | |
dc.contributor.author | Castro-Iglesias, Ángeles | |
dc.contributor.author | López-Calvo, Soledad | |
dc.contributor.author | Martín-Herranz, Isabel | |
dc.contributor.author | Míguez-Rey, Enrique | |
dc.contributor.author | Cid-Silva, Purificación | |
dc.date.accessioned | 2022-11-21T11:40:41Z | |
dc.date.available | 2022-11-21T11:40:41Z | |
dc.date.issued | 2021-10-14 | |
dc.identifier.citation | Rotea-Salvo S, Martínez-Pradeda A, Fernández-Oliveira C, Giménez-Arufe V, Balboa-Barreiro V, Margusino-Framiñán L, Mena-De-Cea Á, Vázquez-Rodríguez P, Castro-Iglesias Á, López-Calvo S, Martín-Herranz I, Míguez-Rey E, Cid-Silva P. Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort. Eur J Hosp Pharm. 2023 Jul;30(4):221-226. | es_ES |
dc.identifier.issn | 2047-9956 | |
dc.identifier.uri | http://hdl.handle.net/2183/32087 | |
dc.description.abstract | [Abstract] Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) and dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) are currently available for HIV patients. Objectives: This study evaluated modifications in the renal safety profile in a large real-world cohort of patients who had received EVG/c/FTC/TAF or DTG/ABC/3TC. Methods: A retrospective observational study of HIV-infected patients who received EVG/c/FTC/TAF or DTG/ABC/3TC between March 2015 and June 2019 at a reference hospital in north-western Spain was conducted. Epidemiological, clinical, immunovirological data and information regarding antiretroviral therapy were recorded. The statistical differences between treatments were calculated. Results: A total of 457 patients were evaluated, 266 using EVG/c/FTC/TAF and 191 using DTG/ABC/3TC. Up to week 120, serum creatinine improved in both study groups among experienced patients (EVG/c/FTC/TAF 1.01±0.24 vs 0.91±0.19, p<0.001; DTG/ABC/3TC 1.08±0.24 vs 1.02±0.31, p<0.001), while in naïve patients serum creatinine remained stable compared with baseline. Statistically significant differences were found in serum creatinine when comparing both treatments at week 48 in experienced (0.94±0.21 vs 1.09±0.28, p<0.001) and naïve patients (0.89±0.16 vs 1.06±0.20, p=0.001), and among experienced patients at week 120 (0.91±0.19 vs 1.02±0.31, p=0.015) for the EVG/c/FTC/TAF and DTG/ABC/3TC groups, respectively. During the follow-up, 39 patients in EVG/c/FTC/TAF and 33 in DTG/ABC/3TC (p=0.449) discontinued treatment. The main reason for stopping treatment was adverse events, which were similar in both groups. Conclusions: During the follow-up, patients experienced changes that were not clinically relevant in both treatment groups. Differences in renal events were not found. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BMJ | es_ES |
dc.relation.uri | http://dx.doi.org/10.1136/ejhpharm-2021-002896 | es_ES |
dc.rights | This article has been accepted for publication in European Journal of Hospital Pharmacy following peer review, and the Version of Record can be accessed online at BMJ web page. | es_ES |
dc.subject | HIV | es_ES |
dc.subject | Clinical medicine | es_ES |
dc.subject | Drug-related side effects and adverse reactions | es_ES |
dc.subject | Hospital | es_ES |
dc.subject | Laboratories | es_ES |
dc.subject | Safety | es_ES |
dc.title | Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.access | info:eu-repo/semantics/openAccess | es_ES |
UDC.journalTitle | European Journal of Hospital Pharmacy | es_ES |
Ficheiros no ítem
Este ítem aparece na(s) seguinte(s) colección(s)
-
INIBIC-VC - Artigos [39]